CTLA4 and neoplasm: In previous studies, it was found that the chronic lymphocytic leukemia (CLL) patients who received ibrutinib treatment markedly diminished PD-1 and CTLA-4 expression on T cells and ibrutinib treatment augmented ICB in tumor models in Balb/c mice32,33.